* Only Micardis^® (telmisartan) 80-mg tablets are indicated for cardiovascular risk reduction. All other MICARDIS and Micardis^® HCT (telmisartan and hydrochlorothiazide) tablets dosages are indicated for the treatment of hypertension only. MICARDIS 80 mg is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors. High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin-dependent) with evidence of end-organ damage. MICARDIS can be used in addition to other needed treatment (such as antihypertensive, antiplatelet, or lipid-lowering therapy). Studies of telmisartan in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves. Use of telmisartan with an ACE inhibitor is not recommended.¹

^† TWYNSTA is not indicated for cardiovascular risk reduction. Base the choice of TWYNSTA as an initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of TWYNSTA tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination, compared with monotherapy, when deciding whether to use TWYNSTA tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk.²

^‡ Certain restrictions may apply. Void where prohibited by law and for product dispensed in Massachusetts. Product dispensed pursuant to terms of voucher shall not be submitted to any third-party payer, public (eg, Medicaid or any other similar federal or state healthcare program) or private, for reimbursement.

^§ Limit one 30-Day FREE Trial Offer per patient—for up to 30 tablets. Valid for first-time MICARDIS users only. Redeem for MICARDIS only when presented with a signed prescription for MICARDIS.

** Dosage must be individualized. In the treatment of hypertension, the usual starting dose of MICARDIS tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20-80 mg. For patients who need even greater efficacy, MICARDIS HCT is available in 40/12.5-mg, 80/12.5-mg, and 80/25-mg tablets. Available as a unit dose. In the treatment of cardiovascular risk reduction, the recommended dose of MICARDIS is 80 mg once a day. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality. When initiating MICARDIS therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended and, if appropriate, adjustment of medications that lower blood pressure may be necessary.¹